In response to a critical nationwide shortage of atropine sulfate injections, Ritedose has announced the release of its prefilled, single-dose syringe of Atropine Sulfate Injection (1.2 mg/3 mL or 0.4 mg/mL). This launch adds to the company’s growing hospital product portfolio and provides an immediate, reliable option for healthcare facilities facing supply chain challenges. READ MORE

Meeting an Urgent Need

Atropine sulfate is a life-saving medication used to treat conditions such as bradycardia (abnormally slow heart rate), poisoning by certain nerve agents or insecticides, and as part of advanced cardiac life support protocols. Due to its importance in emergency and critical care settings, shortages can have serious implications for hospitals and patients alike.

Ritedose’s new single-dose syringe is designed to alleviate this shortage by offering a ready-to-use, sterile solution that simplifies administration and reduces the need for in-house compounding or dilution. The syringe comes pre-filled, clearly labeled, and color-coded for quick identification—making it ideal for high-pressure clinical environments.

Key Features of the New Atropine Product

  • Ready-to-Use Format
    The syringe is prefilled and requires no further preparation, helping clinicians deliver treatment faster in emergency situations.
  • Standardized Concentration
    Each syringe contains a consistent 0.4 mg/mL concentration, minimizing variability and ensuring accurate dosing every time.
  • Enhanced Safety Through Labeling and Color Coding
    Each unit follows industry standards for color coding and labeling, helping reduce the risk of medication errors when seconds matter most.
  • Convenient Shelf Life
    The syringe maintains stability for up to 60 days at room temperature, allowing hospitals more flexibility in managing stock and reducing waste.
  • Supports National Hospital Network
    This launch completes a series of twelve critical-care products introduced by Ritedose over the past six months—each one developed to support hospital pharmacies and emergency departments across the United States.

Ritedose’s Commitment to Quality and Safety

Ritedose has earned a reputation as one of the most dependable sterile pharmaceutical manufacturers in the country. With decades of experience in aseptic production and advanced blow-fill-seal (BFS) technology, the company has supplied billions of doses to hospitals, clinics, and government agencies without interruption.

Every step of the manufacturing process—from formulation to final packaging—is conducted under strict quality controls. This ensures that products like the new atropine sulfate syringe meet or exceed the highest standards for purity, consistency, and reliability.

Strengthening the Healthcare Supply Chain

By launching this product, Ritedose not only addresses an immediate shortage but also strengthens the broader healthcare supply chain. Hospitals benefit from reduced preparation time, lower error potential, and a steady supply of a vital medication. Patients benefit from faster, safer care during emergencies.

The introduction of the single-dose atropine syringe is a clear demonstration of Ritedose’s mission: to provide accessible, high-quality, ready-to-use medications that improve patient outcomes and support the healthcare professionals who depend on them.